Immunology · IL-12/23 Inhibitor
The FDA's acceptance of the supplementary application for STELARA is significant as it suggests potential label expansion, which could strengthen its competitive position in the immunology market. Portfolio teams should closely monitor this development to assess its implications for market share and strategy.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/18/2026, 12:31:56 PM
Assessment confidence: 57% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's acceptance of the supplementary application for STELARA is significant as it suggests potential label expansion, which could strengthen its competitive position in the immunology market. Portfolio teams should closely monitor this development to assess its implications for market share and strategy. Regulatory context from FDA (FDA AP — STELARA (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (4 high-relevance).
Portfolio teams should assess the potential impact of this supplementary application on STELARA's market share and competitive strategy. The strongest clinical anchor is Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov), sponsor/company relevance (novartis). In Immunology · IL-12/23 Inhibitor, 6 regulatory and 2 competitive items passed relevance filtering for Centocor Ortho Biotech.
The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma. This acceptance may enhance STELARA's market position against competitors in the immunology space, particularly those targeting IL-12/23 pathways.
Regulatory risk is concentrated around FDA AP — STELARA (SUPPL) (FDA). Entity match (centocor ortho biotech). Relevant agencies in corpus: FDA, MHRA. The acceptance of the supplementary application indicates a positive regulatory trajectory, but the final approval and any label changes will need to be monitored closely.
FDA AP — STELARA (SUPPL)
FDAhigh relevance
Entity match (centocor ortho biotech)
FDA document
View sourceIND Application Reporting: IND Safety Reports
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceInvestigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceResearch: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourceStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceReal-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceAI-Assisted Versus Conventional Orthodontic Diagnosis and Treatment Planning
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma
Humanexa Signalsmedium relevance
Moderate corpus alignment
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEfficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePreclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceRecent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceWedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's acceptance of the supplementary application for STELARA is significant as it suggests potential label expansion, which could strengthen its competitive position in the immunology market. Portfolio teams should closely monitor this development to assess its implications for market share and strategy.
If approved, the label expansion could enhance STELARA's market share and revenue potential, particularly against competitors targeting similar pathways.
The acceptance of the supplementary application indicates a positive regulatory trajectory, but the final approval and any label changes will need to be monitored closely.
Monitor the progress of the supplementary application review and any subsequent announcements regarding label changes.
Track for follow-up milestones; no immediate action required.